The management of recurrent VTE in cancer patients receiving therapeutic anticoagulation: The use of dual anticoagulant therapy combined with an IVC filter

Blood Coagulation and Fibrinolysis

Volumn 21, Issue 8, 2010, Pages 766-769

  Pillai, Arvind R ^a   Olujohungbe, Adebayo ^a   Evans, Manon R ^b   Main, Norman J ^b   Hunt, Beverley J ^c  

^a UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^b ST HELENS AND KNOWSLEY TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

anticoagulation; cancer; recurrent venous thromboembolism

Indexed keywords

CARBOPLATIN; CISPLATIN; DALTEPARIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; PACLITAXEL; WARFARIN;

ADULT; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CASE REPORT; COLON ADENOCARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; DOPPLER FLOWMETRY; FEMALE; HEMICOLECTOMY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERNATIONAL NORMALIZED RATIO; LEG SWELLING; MULTIPLE CYCLE TREATMENT; OVARY ADENOCARCINOMA; PALLIATIVE THERAPY; PRIORITY JOURNAL; VENOUS THROMBOEMBOLISM;

ADULT; ANTICOAGULANTS; COMBINED MODALITY THERAPY; DALTEPARIN; FEMALE; HUMANS; MIDDLE AGED; VENA CAVA FILTERS; VENOUS THROMBOEMBOLISM; WARFARIN;

EID: 78349266465     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e3283401220     Document Type: Article

References (20)

1. Boccaccio C, Comoglio PM. Genetic link between cancer and thrombosis. J Clin Oncol 2009; 27:4827-4833.
2. Lyman G, Khorana AA. Cancer,clotsand consensus: newunderstanding of an old problem. J Clin Oncol 2009; 27:4821-4826.
3. Falanga A, Marchetti M. Venous thromboembolism in the hematological malignancies. J Clin Oncol 2009; 27:4848-4857.
4. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343:1846-1850.
5. Lee AY. Anticoagulation in the treatment of established venous thromboembolism in patients with cancer. J Clin Oncol 2009; 27:4895-4901.
6. Khorana AA. Cancer and thrombosis: implications of published guidelines for clinical practice.Ann Oncol 2009; 10:1619-1630.
7. Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, et al. American Society of Clinical Oncology guideline: recommendations forvenous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25:5490-5505. (Pubitemid 350232226)
8. Greenfield LJ. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: The PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation 2005; 112:416-422.
9. Carrier M, Le Gal G, Cho R, Tierney S, Rodger M, Lee AY. Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients. J Thromb Haemost 2009; 5:760-765.
10. Kasthuri RS, Mark B, Mackman N. Role of tissue factor in cancer. J Clin Oncol 2009; 27:4834-4838.
11. Partsch H, Kechavarz B, Mostbeck A, Köhn H, Lipp C. Frequency of pulmonary embolism in patients who have ilio-femoral deep vein thrombosis and are treated with once-or twice-daily low-molecular-weight heparin. J Vasc Surg 1996; 24:774-782.
12. Franchini M, Montagnana M, Targher G, Manzato F, Lippi G. Pathogenesis, clinical and laboratory aspects of thrombosis in cancer. J Thromb Thrombolysis 2007; 24:29-38.
13. Franchini M, Montagnana M, Favaloro EJ, Lippi G. The bidirectional relationship of cancer and hemostasis and the potential role of anticoagulanttherapy in moderating thrombosisand cancerspread. Semin Thromb Hemost 2009; 35:644-653.
14. Samama M, Gerotziafas GT. Comparative pharmacokinetics of LMWHs. Semin Thromb Hemost 2000; 26:31-38.
15. Eriksson BI, Söderberg K, Widlund L, Wandeli B, Tengborn L, Risberg B. A comparative study of three low-molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthyvolunteers. Thromb Haemost 1995; 73:398-401.
16. Franchini M, Veneri D, Lippi G. The potential role of recombinant activated FVII in the management of critical hemato-oncological bleeding: a systematic review. Bone Marrow Transplant 2007; 39:729-735.
17. Rana P, Levine MN. Prevention of thrombosis in ambulatory patients with cancer. J Clin Oncol 2009; 27:4885-4888.
18. Weitz JI. Potential of new anticoagulants in patients with cancer. Thromb Res 2010; 125:30-35.
19. Benmira S, Banda ZK, Bhattacharya V. Old versus new anticoagulants: focus on pharmacology. Recent Pat Cardiovasc Drug Discov 2010; 2:120-137.
20. Gómez-Outes A, Lecumberri R, Pozo C, Rocha E. Newanticoagulants: focus on venous thromboembolism. Curr Vasc Pharmocol 2009; 3:309-329.